Drug design, discovery and development and their safety or efficacy on human body
DOI:
https://doi.org/10.30574/gscbps.2021.17.2.0330Keywords:
Definition, Molecular target, Discovery, New drugs investigation, Clinical research, Clinical trialsAbstract
Drug Design, often mentioned as rational drug design or just rational design. It is defined as the study of the shape of molecules in order to determine how they will bind receptors on cells or combine with other molecules. It is based on molecular shape or architecture is an alternative to blindly testing hundreds of molecules to see if one or more of them will bind cellular or molecular targets. The drug is an organic molecule, when it is bind to target site it can either inhibit or activate the function of a bio-molecule which results in therapeutic benefit.
Metrics
References
SK Manirul Haque and Elaref S. Ratemi. Drug Development and analysis review. Journal of Pharmaceutical Chemistry Journal. 2017; 50: 837-850.
Shu-Feng Zhou and Wei-Zhu Zhong. Drug Design and Discovery: Principles and Applications. Journal of Molecules. 2017; 22: 279-285.
Joseph A. DiMasi. Ronald W Hansen, Henry G. Grabowski. The price of innovation: new estimates of drug development costs. Journal of Health Economics. 2003; 22: 151-185.
Sandra Kraljevic, Peter J.Stambrook, Kresimir Pavelic, Accelerating drug discovery. European Molecular Biology Organization (EMBO) reports. 2004; 5: 837-842.
Jannatul Ferdows, Tamanna Tasnim and Shayeda shanjeeda Akter. Drug Discovery and development. International Journal of Current Research. 2018; 10: 73682-73684.
Sahoo Biswa Mohan, Dinda S.C., Ravi Kumar B.V.V., Panda J.R. Computational Approaches for Drug Design and Discovery Process. Journal of Current Parma research. 2012; 2: 600-611.
Michael Dickson and Jean Paul Gagnon. Key Factors in the rising cost of new drug discovery and development. Journal of Nature Reviews Drug Discovery. 2004; 3: 417-429.
Richard C. Mohs, Nigel H. Greig , Drug discovery and development: Role of basic biological research. Journal of Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017; 10: 1-7.
Amol B. Deore, Jayprabha R. Dhumane, Hrushikesh V Wagh, Rushikesh B. Sonawane, The Stages of Drug Discovery and Development Process. Asian Journal of Pharmaceutical Research and Development. 2019; 7: 62-67.
JP Hughes, S Rees, SB Kalindjian, KL Philpot. Principles of early drug discovery. British Journal of Pharmacology. 2011; 162: 1239-1249.
Isabella Gashaw, Peter Ellinghaus, Anette Sommer and Khusru Asadullah. What makes a good drug target? Drug Discovery Today. 2011; 175: S24-S30.
Glenn E Croston. The utility of target-based discovery. Expert Opinion on Drug Discovery. 2017; 12: 1-3.
Henning SW, Beste G. Loss-of-function strategies in drug target validation. Current Drug Discovery Technology. 2002; 17–21.
John GH, Martyn NB, Bristol-Myers S. High throughput screening for lead discovery. Burger‗s Medicinal Chemistry and Drug Discovery, 6 th edition, Drug Discovery and Drug Development, Wiley Press. 2002; 2: 37-70.
Patidar AK, Selvam G, Jeyakandan M, Mobiya AK, Bagherwal A, Sanadya G, Mehta R. Lead Discovery and lead optimization: A useful strategy in molecular modification of lead compound in analog design. International journal of drug design and discovery. 2011; 2: 458-463.
V Umashankar, S Gurunathan. Drug discovery: An appraisal, International journal of pharmacy and pharmaceutical sciences. 2015; 7: 59-66.
Thomas J. DiFeo, Ph.D. Drug Product Development: A technical review of chemistry, manufacturing, and controls information for the support of pharmaceutical compound licensing activities. Journal of Drug Development and Industrial Pharmacy. 2003; 29: 939-958.
Pratibha Muntha. Drug Discovery and Development. Journal of Pharmacy and Pharmaceutical Sciences. 2016; 5: 135-142.
Nalaka Gooneratne. Overview of drug development. Academic Entrepreneurship for Medical and Health Scientists. 2019; 1: 1-9.
Krishnasis Chakraborty, KavitaYadav. Drug approval process in US, Europe and India and its regulatory requirements. International Journal of Drug Regulatory Affairs. 2018; 6: 31-39.
Craig A. Umscheid MD, MSCE, David J. Margolis MD, PhD, MSCE and Craig E. Grossman MD, PhD. Key Concepts of Clinical Trials: A Narrative Review. Journal of Postgraduate Medicine. 2015; 123: 194-204.
Ankur Rohilla, Ravi Kumar Singh, Deepti Sharma, Phases of Clinical Trials. International Journal of Pharmaceutical, Chemical and biological sciences. 2013; 3: 700-703.
SB Thorat, SK Banarjee, DD, Gaikwad SL, Jadhav RM, Thorat. Clinical Trial: A Review. International Journal of Pharmaceutical Sciences Review and Research. 2010; 1: 101-106.
The Lancet, Phase 0 trials: a platform for drug development? Lancet 2009; 374: 176.
Jennie. Muglia and John. Di Giouanna! Phase I clinical trials, Journal of Cutaneous Medicine and Surgery. 1998; 2: 236-241.
Nicolas Penel , Marie Vanseymortier , Marie-Edith Bonneterre , Stéphanie Clisant, Eric Dansin, Yvette Vendel , Régis Beuscart, Jacques Bonneterre. Prognostic factors among cancer patients with good performance status screened for phase I trials. Springer Science, 2007; 26: 53-58.
Philip Sedgwick. What are the four phases of clinical research trials? BMJ, 2014; 348: 1-2.
Marc Buyse, Phase III design: principles, © Chinese Clinical Oncology. 2016; 5: 1-13.
Nihad A.M. Tamimi Peter Ellis, Drug Development: From Concept to Marketing. Journal of Nephron Clinical Practice. 2009; 113: 125-131.
Christopher P. Adams and Van V. Brantner. Estimating the cost of new drug development: Is It Really $802 million?, Health affairs. 2006; 25: 420-428.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
